Long-term Efficacy of Moderna, Merck, and Keytruda Melanoma Vaccine Revealed
Moderna and Merck's experimental messenger RNA cancer vaccine, in combination with Merck's Keytruda, has shown promising results in reducing the risk of recurrence or death from melanoma by 49% after three years, according to a midstage trial involving 157 patients. The personalized cancer vaccine, which is custom-built based on a patient's tumors, aims to train the immune system to recognize and attack specific mutations in cancer cells. The positive results could potentially support accelerated approval from regulatory authorities, although further trials and regulatory engagement are still required.